Rabbit p27 Kip1 Polyclonal Antibody | anti-Kip1 antibody

p27 Kip1 (Phospho-T198) Polyclonal Antibody

Cat. Num. AAA3005397

• Gene Names: CDKN1B; KIP1; MEN4; CDKN4; MEN1B; P27KIP1
• Reactivity: Human, Mouse, Rat
• Applications: Western Blot
• Purity: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is >95% (by SDS-PAGE).
• Synonyms: p27 Kip1; Polyclonal Antibody; p27 Kip1 (Phospho-T198) Polyclonal Antibody; Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor; p27; p27Kip1; CDKN1B; KIP1; anti-Kip1 antibody

• Host: Rabbit
• Reactivity: Human, Mouse, Rat
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: p-p27 Kip1 (T198) polyclonal antibody detects endogenous levels of p27 Kip1 protein only when phosphorylated at Thr198.
• Purity/Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is >95% (by SDS-PAGE).
• Form/Format: Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
• Sequence Length: 198

• Applicable Applications for anti-Kip1 antibody: Western Blot (WB)
• Application Notes: WB: 1:500-1:1000
• Immunogen: Synthetic phosphopeptide derived from human p27 Kip1 around the phosphorylation site of Threonine 198.
• Preparation and Storage: Store at 4 degree C short term.; Aliquot and store at -20 degree C long term.; Avoid freeze-thaw cycles.

Western Blot (WB)

(Western Blot (WB) analysis of p-p27 Kip1 (T198) polyclonal antibody at 1:500 dilutionLane1:HEK293T cell lysate treated with EGF (0.1ng/ML,30mins) Lane2:Raw264. 7 cell lysate treated with EGF (0.1ng/ML,30mins) Lane3:H9C2 cell lysate treated with EGF (0.1ng/ML,30mins))

Related Product Information for anti-Kip1 antibody

Cell cycle progression is regulated by a series of cyclin-dependent kinases that consist of catalytic subunits, designated Cdks, and activating subunits, designated cyclins. Orderly progression through the cell cycle requires the activation and inactivation of different cyclin-Cdks at appropriate times. A series of proteins has been recently described that function as "mitotic inhibitors." These include p21, the levels of which are elevated upon DNA damage in G1 in a p53-dependent manner, p16 and a more recently described p16 related inhibitor designated p15. A p21 related protein, p27, has been described as a negative regulator of G1 progression and has been speculated to function as a possible mediator of TGFbeta-induced G1 arrest. p27 interacts strongly with D-type cyclins and Cdk4 in vitro and to a lesser extent with cyclin E and Cdk2.

NCBI and Uniprot Product Information

• NCBI GI #: 4757962
• NCBI GeneID: 1027
• NCBI Accession #: NP_004055.1
• NCBI GenBank Nucleotide #: NP_004055.1
• UniProt Accession #: P46527
• Molecular Weight: ~ 27kDa
• NCBI Official Full Name: cyclin-dependent kinase inhibitor 1B
• NCBI Official Synonym Full Names: cyclin dependent kinase inhibitor 1B
• NCBI Official Symbol: CDKN1B
• NCBI Official Synonym Symbols: KIP1; MEN4; CDKN4; MEN1B; P27KIP1
• NCBI Protein Information: cyclin-dependent kinase inhibitor 1B
• UniProt Protein Name: Cyclin-dependent kinase inhibitor 1B
• Protein Family: Kinesin-like protein
• UniProt Gene Name: CDKN1B
• UniProt Synonym Gene Names: KIP1
• UniProt Entry Name: CDN1B_HUMAN

NCBI Description

This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014]

Uniprot Description

p27Kip1: a cell-cycle regulatory protein that Interacts with cyclin-CDK2 and -CDK4, inhibiting cell cycle progression at G1. May mediate TGF beta-induced g1 arrest. Its degradation is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state.

Protein type: Oncoprotein; Cell cycle regulation; Inhibitor; Protein kinase, regulatory subunit

Chromosomal Location of Human Ortholog: 12p13.1-p12

Cellular Component: nucleoplasm; cytoplasm; cytosol; nucleus; endosome

Molecular Function: cyclin-dependent protein kinase inhibitor activity; protein binding; chaperone binding; protein complex binding; caspase activator activity; Hsp70 protein binding; protein phosphatase binding; transforming growth factor beta receptor, cytoplasmic mediator activity

Biological Process: response to peptide hormone stimulus; negative regulation of kinase activity; nerve growth factor receptor signaling pathway; positive regulation of microtubule polymerization; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; response to estradiol stimulus; negative regulation of cell proliferation; sensory perception of sound; positive regulation of cell proliferation; response to glucose stimulus; negative regulation of mitotic cell cycle; cell cycle arrest; inner ear development; potassium ion transport; response to drug; caspase activation; epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; phosphoinositide-mediated signaling; negative regulation of cyclin-dependent protein kinase activity; negative regulation of cell motility; response to amino acid stimulus; response to cadmium ion; autophagic cell death; positive regulation of protein catabolic process; response to hypoxia; negative regulation of phosphorylation; innate immune response; negative regulation of cell growth; mitotic cell cycle; regulation of cyclin-dependent protein kinase activity; negative regulation of transcription, DNA-dependent; negative regulation of apoptosis; G1/S transition of mitotic cell cycle

Disease: Multiple Endocrine Neoplasia, Type Iv